We believe that every neuromodulation treatment can and should be delivered in a non-invasive way. Our mission is to bring these non-invasive methods to light and bring relief to our patients.
We are focusing on patient safety, comfortable treatment, effectiveness, and easy access.
We want to match the ease of use of pills.
We are developing a technology platform for neuromodulation treatment of chronic diseases, such as Overactive Bladder (OAB).
We focus on the user-friendliness of our medical devices, especially from the viewpoint of safety and effectiveness.
The OAB drugs in current use are more than 20 years old and they are being gradually replaced by generic drugs. Whilst the development of new drugs is like looking for a needle in a haystack. Moreover, there are questions about the safety of certain OAB drugs.
Neuromodulation treatment has been on the market since 1998. Half of all SNM implants have been used within the last 5 years. In 2013, some insurance companies have started reimbursing the PTNS method which doubled its revenues over recent years. These facts illustrate the current trends in patient behaviour. The search for alternative treatment is on the rise and the entire market is moving towards a non-invasive treatment of the disease.
During the past few years, dozens of clinical trials have been conducted and hundreds of professional articles on neuromodulation have been published. Both methods have become reimbursable by health insurance providers, plus they have been gradually spreading throughout the world.